Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: Analysis of persistent and new-onset cytopenia

Cancer

Volumn 119, Issue 21, 2013, Pages 3805-3811

  Strati, Paolo ^a   Wierda, William ^a   Burger, Jan ^a   Ferrajoli, Alessandra ^a   Tam, Constantine ^b   Lerner, Susan ^a   Keating, Michael J ^a   O'Brien, Susan ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

chronic lymphocytic leukemia; combination of fludarabine, cyclophosphamide, and rituximab; cytopenia; prognosis

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BACTERIAL INFECTION; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; CANCER PROGNOSIS; CANCER STAGING; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOPENIA; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HERPES ZOSTER; HUMAN; LEUKEMIA REMISSION; LUNG MYCOSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); POST HOC ANALYSIS; PREVALENCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS REACTIVATION;

CHRONIC LYMPHOCYTIC LEUKEMIA; COMBINATION OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB; CYTOPENIA; PROGNOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MYELOABLATIVE AGONISTS; NEOADJUVANT THERAPY; PANCYTOPENIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VIDARABINE; YOUNG ADULT;

EID: 84886099684     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28318     Document Type: Article

References (26)

1. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4079-4088.
2. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010; 376: 1164-1174.
3. Tam CS, O'Brien S, Wierda W, et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008; 112: 975-980.
4. Gribben JG, O'Brien S,. Update on therapy of chronic lymphocytic leukemia. J Clin Oncol. 2011; 29: 544-550.
5. Bottcher S, Ritgen M, Fischer K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol. 2012; 30: 980-988.
6. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008; 111: 5446-5456.
7. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol. 2005; 23: 4070-4078.
8. Badoux XC, Keating MJ, Wang X, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. Blood. 2011; 117: 3016-3024.
9. Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol. 2010; 28: 1756-1765.
10. Borthakur G, O'Brien S, Wierda WG, et al. Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab-incidence and predictors. Br J Haematol. 2007; 136: 800-805.
11. Tam C, Seymour JF, Brown M, et al. Early and late infectious consequences of adding rituximab to fludarabine and cyclophosphamide in patients with indolent lymphoid malignancies. Haematologica. 2005; 90: 700-702.
12. Carney DA, Westerman DA, Tam CS, et al. Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy. Leukemia. 2010; 24: 2056-2062.
13. Tam CS, Seymour JF, Prince HM, et al. Treatment-related myelodysplasia following fludarabine combination chemotherapy. Haematologica. 2006; 91: 1546-1550.
14. McLaughlin P, Estey E, Glassman A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005; 105: 4573-4575.
15. Zhou Y, Tang G, Medeiros LJ, et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol. 2012; 25: 237-245.
16. Yamazaki S, Nakamura F, Nannya Y, Nakagawa M, Ichikawa M, Kurokawa M,. Early-onset therapy-related myelodysplastic syndrome originating from prolonged myelosuppression after fludarabine-based therapy. Intern Med. 2012; 51: 3427-3430.
17. Uppal GK, Leighton J, Da Costa D, Czulewicz A, Palazzo IE,. Therapy related acute myeloid leukemia with t(10:16): a rare entity. Hematol Rep. 2011; 3: e23.
18. Sarid N, Eshel R, Rothman R, et al. Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia. Eur J Haematol. 2012; 89: 430-431.
19. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol. 2006; 24: 4634-4641.
20. Rassenti LZ, Huynh L, Toy TL, et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med. 2004; 351: 893-901.
21. Dohner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P,. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes. Leukemia. 1997; 11 (suppl 2): S19-S24.
22. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997.
23. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003; 101: 6-14.
24. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011; 377: 42-51.
25. Martell RE, Peterson BL, Cohen HJ, et al. Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB coordinated intergroup study. Cancer Chemother Pharmacol. 2002; 50: 37-45.
26. Ysebaert L, Gross E, Kuhlein E, et al. Immune recovery after fludarabine-cyclophosphamide-rituximab treatment in B-chronic lymphocytic leukemia: implication for maintenance immunotherapy. Leukemia. 2010; 24: 1310-1316.